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Anti-inflammatory Drugs (SOS) projectAbstract
Background: Data on utilization patterns and safety of non-steroidal anti-inflammatory drugs (NSAIDs) in children
are scarce. The purpose of this study was to investigate the utilization of NSAIDs among children in four European
countries as part of the Safety Of non-Steroidal anti-inflammatory drugs (SOS) project.
Methods: We used longitudinal patient data from seven databases (GePaRD, IPCI, OSSIFF, Pedianet, PHARMO,
SISR, and THIN) to calculate prevalence rates of NSAID use among children (0–18 years of age) from Germany,
Italy, Netherlands, and United Kingdom. All databases contained a representative population sample and recorded
demographics, diagnoses, and drug prescriptions. Prevalence rates of NSAID use were stratified by age, sex, and
calendar time. The person-time of NSAID exposure was calculated by using the duration of the prescription supply.
We calculated incidence rates for serious adverse events of interest. For these adverse events of interest, sample size
calculations were conducted (alpha = 0.05; 1-beta = 0.8) to determine the amount of NSAID exposure time that
would be required for safety studies in children.
Results: The source population comprised 7.7 million children with a total of 29.6 million person-years of observation.
Of those, 1.3 million children were exposed to at least one of 45 NSAIDs during observation time. Overall prevalence
rates of NSAID use in children differed across countries, ranging from 4.4 (Italy) to 197 (Germany) per 1000 person-years
in 2007. For Germany, United Kingdom, and Italian pediatricians, we observed high rates of NSAID use among children
aged one to four years. For all four countries, NSAID use increased with older age categories for children older than 11.
In this analysis, only for ibuprofen (the most frequently used NSAID), enough exposure was available to detect
a weak association (relative risk of 2) between exposure and asthma exacerbation (the most common serious
adverse event of interest).
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Conclusions: Patterns of NSAID use in children were heterogeneous across four European countries. The SOS
project platform captures data on more than 1.3 million children who were exposed to NSAIDs. Even larger data
platforms and the use of advanced versions of case-only study designs may be needed to conclusively assess the
safety of these drugs in children.
Keywords: Pharmacoepidemiology, Database, Drug utilization, Health resource utilization, Drug safety, Sample
size, Asthma exacerbation, Self-controlled case series design, Case-crossover designBackground
Non-steroidal anti-inflammatory drugs (NSAIDs) are fre-
quently used for their analgesic, antipyretic, and anti-
inflammatory effects, even in children. NSAIDs were
the tenth most frequently prescribed drug in the age
group 2–11 years (33 users/1000 person years) and the
sixth most frequently prescribed drug in age group 12–
18 years (57 users/1000 person years) in a combined
primary care database study conducted in Italy, the
Netherlands and the United Kingdom [1].
The Safety of Non-steroidal Anti-inflammatory Drugs
(SOS) project is a research and development project
funded by the Health Area of the European Commission
under the Seventh Framework Programme, with the aim
to assess the cardiovascular and gastrointestinal safety of
NSAIDs, in particular with respect to children [2]. In the
SOS project, prior to conducting novel observational
studies on NSAID safety by linking seven databases from
four European countries, data from published clinical
trials and observational studies have been investigated
by literature review and meta-analysis. This literature
review revealed that safety of NSAIDs in children has
not been adequately assessed in clinical trials nor post-
marketing studies since most of these studies were too
small and short to detect infrequent adverse events. In
addition, the Paediatric Working Party of the European
Medicines Agency (EMA) has identified the need to
study safety issues related to specific NSAIDs, such as
diclofenac, ibuprofen, ketoprofen, and naproxen [3].
In this study, as part of the SOS project, we aimed to
investigate NSAID utilization patterns among children
in four European countries and assess statistical power
to study NSAID safety for ten adverse events of interest.Methods
Data sources
Data for this study were obtained from seven longitudinal
observational databases from four European countries
involving medical data from more than 32 million people.
Three primary care databases and four hospital discharge
or administrative databases provided data from Germany
(DE), Italy (IT), the Netherlands (NL) and the United
Kingdom (UK) (Table 1). All databases recorded demo-
graphics, diagnoses, and drug prescriptions. Participatingdatabases contain a representative sample of the respective
populations based on age and sex. This analysis was exclu-
sively based on routinely collected anonymized data and
adhered to the European Commission’s Directive 95/46/EC
for data protection. The protocol for this drug-utilization
study was approved by the databases’ scientific and ethical
advisory boards or regulatory agencies where applicable.
The databases are described as follows.
German pharmacoepidemiological research
database (GePaRD)
GePaRD is a claims database and consists of claims data
from four German statutory health insurance (SHI) pro-
viders. It covers about 14 million persons throughout
Germany who have at any time between 2004 and 2008
been enrolled in one of the four SHIs. The database
population represents approximately 17% of the German
population. Available data contain demographic informa-
tion and information on hospital discharges, outpatient
physician visits, and outpatient dispensing of prescribed
medications in the pharmacies. Hospital diagnoses are
coded according to the German Modification of the
International Classification of Diseases, 10th Revision
(ICD-10 GM) with at least 4 digits [4]. Information on
drug prescriptions is linked to a pharmaceutical reference
database providing information on the World Health
Organization’s (WHO) anatomical-therapeutic-chemical
(ATC) code [5], prescribed quantity (number of packages),
prescription date, dispensation date, substance, product
name, manufacturer, pack size, strength, defined daily
dose (DDD), and pharmaceutical formulation. All involved
SHIs, the Federal Ministry of Health (for data from
multiple federal states) and the health authority of Bremen
(for data from the Federal State of Bremen) approved the
use of the data for this study.
The Health Improvement Network (THIN) database
THIN is a longitudinal database of primary care medical
records from more than 10 million people in the UK.
Some electronic records date back to 1985. Currently,
the database has 3.6 million active patients registered.
Data recorded in THIN include demographics, diagnoses,
symptoms, prescriptions, life style information such as
smoking or alcohol consumption, test results, height,
Table 1 Study population and database characteristics
Pediatric source population
(Age 0 to 18 years)
Database Country Type of database Diagnoses captured with: Drugs captured with: Study period Number of persons Person-years of
observation
Number of
NSAID users
GePaRD Germany Claims database ICD-10-GM ATC 2005 - 2008 2,992,087 7,056,919 925,667
THIN United Kingdom General practice database READ BNF/Multilex/ATC 1999 – 2008 1,261,668 5,198,351 227,927
IPCI Netherlands General practice database ICPC and free text ATC 1999 – 2011 250,296 618,479 12,002
PHARMO Netherlands Record linkage system ICD-9-CM ATC 1999 – 2008 594,800 2,914,576 82,233
OSSIFF Italy National Health Services registry (claims) ICD-9-CM ATC 2000 – 2008 675,197 3,671,014 22,760
SISR Italy National Health Services registry (claims) ICD-9-CM ATC 2002 – 2009 1,744,525 9,111,635 34,308
Pedianet* Italy General practice pediatric database ICD-9-CM and free text ATC 2000 – 2010 221,115 1,064,867 34,575
Total 7,739,688 29,635,841 1,339,472
*Pedianet only includes children up to the age of 14 years.
ICD-10-GM: International Classification of Diseases, 10th Revision German Modified; ICD-9-CM: International Classification of Diseases, 9th Revision Clinically
Modified; ICPC: International Classification for Primary Care; ATC: Anatomical Therapeutic Chemical classification; BNF: British National Formulary.
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request, specialist letters and hospital discharge sum-
maries. Diagnoses and symptoms are recorded using
READ codes. Information on drug prescriptions is coded
with MULTILEX product dictionary, mapped to ATC
codes, and contains dose and duration. Approval for
this study has been obtained from the Scientific Review
Committee for the THIN database.
Integrated Primary Care Information (IPCI) database
The IPCI database is a dynamic longitudinal primary care
research database from NL initiated in 1992. Currently, it
covers about one million people from 150 active general
practices. Symptoms and diagnoses are recorded using
the International Classification for Primary Care (ICPC
[6]) and free text and hospital discharge summaries.
Information on drug prescriptions comprises official
label text, quantity, strength, prescribed daily dose and
is coded according to the ATC classification. Approval
for this study has been obtained from the IPCI-specific
ethical review board ‘Raad van Toezicht’.
PHARMO database
The PHARMO medical record linkage system is a
population-based patient-centric data tracking system
of 3.2 million community-dwelling inhabitants from NL.
Data have been collected since October 1994. The drug
dispensing data originate from out-patient-pharmacies.
Via the Dutch National Medical Register (LMR) hospital
admissions are collected with ICD-9-clinically modified
(CM). Information on drug prescriptions is coded accord-
ing to the ATC classification.
Osservatorio Interaziendale per la Farmacoepidemiologia
e la Farmacoeconomia (OSSIFF) database
In the Italian National Health Service (NHS), the Local
Health Authority is responsible for the health of the
citizens in a given geographical area, usually a province.
In 2006, eight authorities have established a network
named OSSIFF, accounting for a population of about
3.8 million people. Hospital diagnoses are coded according
to ICD-9-CM. Prescriptions are coded according to the
ATC coding system, and additionally prescription date,
number of prescribed units, drug strength and the defined
daily dose (DDDs) of the active entity are available.
Sistema Informativo Sanitario Regionale (SISR) database
In the Italian SISR database, data are obtained from the
electronic healthcare databases of the Lombardy region.
Lombardy is the largest Italian region with about nine
million inhabitants, about 16% of the population of
Italy. This population is entirely covered by a system of
electronically linkable databases containing information
on health services reimbursable by the NHS. The SISRdatabase has complete population coverage and data is
available from 2002. Via the ICD-9-CM dictionary and
ATC classification, the database captures information
on diagnoses from hospitalizations and drugs. Because
OSSIFF covers a subset of patients covered by SISR,
this database excluded the common subset of patients
to avoid overlap.Pedianet database
The Italian Pedianet database is a primary care pediatric
database comprising the clinical data of about 160 family
pediatricians (FPs) distributed throughout Italy. In Italy
all children until the age of 14 years are registered
with an FP. Pedianet has been built up since 1999. By
December 2010, Pedianet database contained data on
370,000 children. Information on all drugs (date of
prescription, ATC code, substance, formulation, quantity,
dosing regimen, legend duration, indication, reimbursement
status), symptoms and diagnoses are available in free
text or coded by the ICD-9 system.Data sharing and data extraction
In accordance with European data protection standards,
neither personal identifiers nor other patient-level data
were shared across countries. Data were extracted and
processed locally by Jerboa© software, a software developed
and validated at Erasmus University Medical Center in
Rotterdam [7]. The Jerboa software calculated drug-
utilization and disease-incidence measures for each
database stratified by age, sex, and calendar time. The
concept of a distributed data network with a common
format of input files has been described previously [7].
The aggregated and de-identified data were stored
centrally at a data warehouse (DW) in Milan, Italy.
Assigned persons were allowed to gain access to the DW
via a secured token, assigned to an Internet Protocol
(IP)-address.
Three input files were extracted from each database
locally according to a pre-specified common format
containing information on: (i) patient characteristics
such as date of birth, sex, and registration date; (ii)
NSAID prescriptions or dispensing (ATC code M01A)
including duration of supply, and (iii) diagnoses and
their corresponding date through ICD-10, READ, ICD-9,
ICPC codes or free text. The observation time for each
patient started 365 days after registration with a practice
or health insurance system. For children who were born
into the database, observation started at date of birth. The
observation period ended at the earliest of the following
dates: turning 14 (Pedianet) or 18 years of age, transfer
out of the practice or insurance system, death, or last data
collection. The study period varied between databases
according to data availability (Table 1).
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The pediatric part of the SOS project considered the
following ten outcomes that are of clinical relevance in
children: asthma exacerbation, anaphylactic shock, upper
gastrointestinal complications, stroke, heart failure, acute
renal injury, Stevens–Johnson syndrome, acute liver injury,
acute myocardial infarction, and Reye’s syndrome [8-16].
To extract the events of interest in the participating
databases, the medical concepts were first mapped
using the Unified Medical Language System (UMLS), a
biomedical terminology integration system handling
more than 150 medical dictionaries [17]. This process
was needed as the clinical information captured by the
different databases is collected using four different
disease terminologies (ICPC, ICD-9, ICD-10, and READ
codes) and free text in Dutch and Italian. For each medical
concept, UMLS identified corresponding codes for each
of the four terminologies. This UMLS-based approach
was developed in the EU-ADR project and has been
described in more detail elsewhere [18]. Subsequently,
the codes were extracted in a centralized process (referred
to as the codex method) and reviewed by a panel of
medically trained investigators according to event defini-
tions. Extraction queries were reviewed in case of large,
unexpected discrepancies. This harmonization process
enabled a more homogeneous identification of events
across databases using different coding-based algorithms.
Statistical analyses
Drug utilization measures
For each database, the prevalence rate of NSAID use
was calculated by dividing the number of prevalent NSAID
users by the person-time of observation, stratified by
age, sex, calendar year, and calendar month. The reference
calendar year was 2007. The person-time of NSAID
exposure was calculated by using the duration of
the prescription supply. Relative prevalence rates (in
percentages) were calculated by dividing the absolute
prevalence rate by the mean prevalence rate within
each database for each calendar month and one-year
age category.
Incidence rates for events of interest
We calculated incidence rates (IRs) per 100,000 person-
years for each of the events of interest for each database
and performed direct standardization using the WHO
World Standard Population as reference to account for
age differences when comparing the overall diagnosis
rates (standardized IRs; SIRs) [19]. We only considered
the first recorded occurrence of the event of interest
after a run-in period of one year. To calculate the overall
IR in the SOS platform, the total number of events
across databases was divided by the person time captured
in all databases.Required amount of drug exposure to detect safety signals
To determine the usability of the SOS database platform
for the study of NSAID safety with respect to adverse
events of interest in children, we calculated the person-
years of exposure required to detect a drug-event asso-
ciation over varying magnitudes of relative risks (RR),
using RRs of 2 (weak association), 4 (moderate association),
and 6 (strong association), a one-sided significance level
(α) of 0.05, and a power (1-β) of 80%. To estimate the
required exposure for specific strengths of association
we used a previously published sample size formula
[20]. The required exposure time was compared to the
person time of exposure to ibuprofen to assess whether
the database platform is sufficient in current size, or
expansion would be necessary for adequate evaluation
of safety.
Results
Source population
The pediatric population of the SOS platform network
comprised 7.7 million children and adolescents (0 to
18 years) contributing 29.6 million person-years (PYs) of
observation between 1999 and 2011 (Table 1). Of the
observation time, 11.5% were for children less than
2 years of age, 20.8% for children aged 2 to ≤5 years,
31.5% for children aged 6 to ≤11 years and 36.3% for
adolescents aged 12 to ≤18 years. Of the combined
pediatric population, 51.4% were male. The database
which contributed most person time was SISR, followed
by GePaRD and THIN, with different observation
periods across databases according to data availability
(Table 1).
Prevalence of NSAID use
Of the 7.7 million children and adolescents, 1,339,472
(17.3%) used one of the 45 NSAIDs for at least one day
during observation time (Table 1). This generated a total
exposure of 61,739 PYs of NSAID exposure. In GePaRD,
31% of children used NSAIDs, which is in contrast
with lower percentages in SISR (2%), OSSIFF (3%),
and IPCI (5%).
The overall prevalence rate of NSAID use was 56 per
1,000 person-years in 2007, and ranged between 4.4 in
OSSIFF and 197 in GePaRD. Figure 1 shows that the
annual prevalence of NSAID use varies between age
groups and countries. There were two distinct prescription
patterns. The first pattern showed that the prevalence
of NSAID use was relatively low in young children and
substantially higher for children older than 8 years of
age for IPCI, PHARMO, OSSIFF and SISR. In contrast,
the use of NSAIDs was most prevalent before the age
of four in children for GePaRD, THIN and Pedianet. In
GePaRD, prevalence rates reached values of 483 per
1000 PYs (48% of children) for three-year-olds in 2007.
Prevalence rate by age (per 1000 person-years) Prevalence rate by calendar month (per 1000 person-months) 
Relative prevalence rate by age Relative prevalence rate by calendar month
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Figure 1 Prevalence rates (top) and relative prevalence rates (bottom) of NSAID use for the calendar year 2007, for each database, by
age (left) and by calendar month (right).
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categories of thirteen and eight years for GePaRD and
THIN, respectively. The prevalence rates of NSAID use
increased thereafter. Figure 2 shows that the overall
annual prevalence rates of NSAID use in 2007 were
higher for females than for males, especially for THIN,
IPCI and PHARMO. The sex distribution was equal for
all databases until the age of ten, but the prevalence
rates diverge after that age with higher rates for females
in GePaRD, THIN, IPCI and PHARMO. Annual prevalence
of NSAID use was relatively stable over calendar time
for most databases. There was a tendency of slightly
decreasing prevalence rates after the year 2003 for OSSIF
and SISR while prevalence rates were steadily increasing
for THIN and GePaRD (data not shown).
Monthly prevalence rates of NSAID use showed that
prescriptions were most common in February and less
frequent in summer months. This seasonal pattern of
NSAID use in children and adolescents was especially
seen in GePaRD (August: 19; February: 45), THIN (August:
7.5; February: 14), and Pedianet (August: 2.1; February:10 – all numbers per 1000 person months in 2007)
(Figure 1). Mean duration of NSAID prescription or
dispensing was highest in THIN and SISR (15.4 and
15.8 days) and lowest in Pedianet (4.8 days).
Individual NSAIDs
On average, 26 NSAIDs were prescribed or dispensed
per database with a range between 19 for IPCI and 32
for OSSIFF. Of those, ibuprofen was the most frequently
used NSAID, accounting for 69.3% of total person time
of NSAID exposure. Diclofenac and naproxen were
also available in all databases and accounted for 13.0%
and 6.3% of the total person time of NSAID exposure,
respectively. Distribution of NSAID use was heterogeneous
between countries. Ibuprofen was the most frequently used
NSAID in GePaRD, THIN and Pedianet, while nimesulide
was most frequent in the other two Italian databases
(OSSIFF and SISR), followed by ketoprofen and naproxen.
Together with ibuprofen and ketoprofen, morniflumate
was common in Pedianet. In the Netherlands (IPCI and
PHARMO), diclofenac, naproxen and ibuprofen were most
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Figure 2 Prevalence rates of NSAID use for the calendar year 2007, for each database, stratified by sex.
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were only available in Italy, while lonazolac and parecoxib
were only available in the GePaRD database (Germany),
and etodolac, fenbufen, and fenoprofen were only
prescribed in THIN (UK). In IPCI and PHARMO (both
from NL) a fixed combination of diclofenac and miso-
prostol (a prostaglandin E1 analogue used for gastro-
protection) was frequently prescribed to adolescents,
whereas this was not common in other databases (data
not shown). In all databases except OSSIFF and SISR
(both from IT), the three most frequently used NSAIDs
accounted for more than 80% of the total person-years
of NSAID exposure. Proprionic acid derivates (such as
ibuprofen; ATC code M01AE) were by far most common
in all databases except OSSIFF and SIRS. OSSIFF and SIRS
showed highest prescription rates for cyclooxygenase-2-
selective NSAIDs (coxibs; 12% and 8.3% respectively, as
compared to an average of 1.2% for the other database).
Required exposure time for NSAID safety assessment
in children
Table 2 shows the number of NSAIDs that have enough
exposure to detect weak (RR = 2), moderate (RR = 4) or
strong (RR = 6) associations for the ten adverse events
of interest. The stronger the association and the more
common the event to be studied, the lower is the
required exposure time for a specific NSAID substance.
Thus, the lower the required exposure time for a specific
NSAID substance the higher is the number of drugs
that can be studied, which is expected from the power
calculations. Taking asthma exacerbation as example
with the highest incidence rate (IR) of 82/100 000 PYs,
only one NSAID (ibuprofen) had enough person time
exposure (9,788 person-years or more) to detect a weak
association (RR = 2). To assess a moderate (RR = 4) or a
strong (RR = 6) association with asthma exacerbation,four and six NSAID substances had adequate person
time of exposure, respectively. None of the drugs accounted
for adequate exposure time to detect a strong association
for the following rare events: Stevens-Johnson syndrome,
acute liver failure, acute myocardial infarction, and
Reye’s syndrome. For a very rare outcome such as
Reye’s Syndrome, the SOS platform would require 998
times as much exposed person time in order to study a
weak association for ibuprofen (the most commonly
used NSAID) (Table 2). Table 3 shows for which events
of interest sufficient person time was available to study
a strong association (RR = 6) for the most frequently
used NSAIDs.
Discussion
In the SOS project, the combined source population of
children and adolescents (0 to 18 years of age) from
seven databases from four European countries involved
7.7 million children and adolescents and generated 29.6
million person-years of observation between 1999 and
2011. Of these, 1.3 million children received NSAID
prescriptions during the studied periods in the respective
databases. Overall, 56 children/adolescents out of 1000
received an NSAID prescription per year. This varied
largely between 4 per 1000 in OSSIFF to 197 per 1000
in GePaRD in the pediatric population. In general, one
could conclude that the annual prevalence of prescribed
NSAIDs is lowest in Italy, followed by the Netherlands,
the United Kingdom and highest for Germany. Also, in
all databases except the Italian ones, females received
more NSAID prescriptions than males, mainly related
to diverging prevalence rates in adolescence (Figure 2).
When considering the age-specific prevalence rates, the
high rates in the very young for the German database
GePaRD compared to the other European countries are
striking (Figure 1). For GePaRD values reach prevalence
Table 2 Required exposure time needed to investigate NSAID safety in children for ten potential adverse events with varying incidence rates considering a
weak, moderate or strong association
Event type IR/100,000
PY
Weak association Moderate association Strong association
(RR = 2) (RR = 4) (RR = 6)
Required
exposure (PY)
Drugs Expan-sion Required exposure (PY) Drugs Expan-sion Required exposure (PY) Drugs Expan-sion
N (%) N (%) N (%)
Asthma exacerbation 82.12 9,788 1 (2.2) 0 1,499 4 (8.9) 0 669 6 (13.3) 0
Anaphylactic shock 4.29 187,358 0 (0) 4 28,687 1 (2.2) 1 12,809 1 (2.2) 0
Upper gastrointestinal complication 2.64 303,990 0 (0) 7 46,545 0 (0) 1 20,782 1 (2.2) 0
Stroke 2.07 388,410 0 (0) 9 59,471 0 (0) 1 26,554 1 (2.2) 1
Heart failure 1.57 511,927 0 (0) 12 78,384 0 (0) 2 34,998 1 (2.2) 1
Acute renal failure 1.40 573,919 0 (0) 13 87,875 0 (0) 2 39,236 1 (2.2) 1
Stevens–Johnson syndrome 0.56 1,438,097 0 (0) 34 220,194 0 (0) 5 98,315 0 (0) 2
Acute liver failure 0.46 1,741,369 0 (0) 41 266,629 0 (0) 6 119,048 0 (0) 3
Acute myocardial infarction 0.12 6,918,411 0 (0) 162 1,059,310 0 (0) 25 472,974 0 (0) 11
Reye’s syndrome 0.02 42,663,537 0 (0) 998 6,532,413 0 (0) 153 2,916,676 0 (0) 68
IR: incidence rate; RR: relative risk; PY: Person years.
Drugs N (%): Number of drugs that have enough PY of exposure in the SOS platform to detect a potential signal for the respective event of interest (in brackets the proportion of NSAIDs with enough PY exposure of
all 45 NSAIDs).
Expansion: magnitude of enlargement of PY exposure in the SOS platform necessary for assessment of each safety outcome for ibuprofen (exposed person time 42,768 PY) given the specified relative risk that should
be detected with α<0.05 (one-sided) and ß = 0.20.
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Table 3 Is sufficient exposure time available in the SOS platform to investigate the particular event of interest given an expected relative risk of six stratified
by NSAID substance?
Given an RR of 6:
ATC SUM PYs % PYs Asthma
exacerbation
Anaphylactic
shock
Upper gastrointestinal
complication
Stroke Heart
failure
Acute renal
failure
Stevens–Johnson
syndrome
Acute liver
failure
Acute myocardial
infarction
Reye’s
syndrome
Total NSAIDs 61,739 100 X X X X X X
Ibuprofen* 42,768 69.3 X X X X X X
Non-ibuprofen+ 18,971 30.7 X X (X)
Diclofenac# 8,000 13.0 X
Naproxen^ 3,878 6.3 X
Mefenamic acid 2,297 3.7 X
Ketoprofen& 946 1.5 X
Nimesulide 925 1.5 X
Piroxicam 519 0.8
Indometacin 440 0.7
Meloxicam 328 0.5
Celecoxib 258 0.4
Rofecoxib 247 0.4
Etoricoxib 218 0.4
X: denotes that enough person time is available for detection of a RR of 6 with α = 0.05 (one-sided) and ß = 0.20; (X): denotes that enough person time is available for detection of a RR of 6 with α = 0.1 (one-sided)
and ß = 0.20, exclusive to the use of α = 0.05; PYs: denotes Person years.
+including all NSAID preparation without ibuprofen.
*including combinations with ibuprofen.
#including combinations with diclofenac.
^including combinations with naproxen.
&including combinations with ketoprofen.
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3-year-olds. In Germany, United Kingdom and Italy,
ibuprofen is the drug of choice beside paracetamol
(acetaminophen) for fever in children [21-23], whereas
in the Netherlands paracetamol is considered first [24].
In THIN and Pedianet prevalence rates were also
higher in children below the age of 4, whereas for other
databases prevalence rates were steadily increasing
with age and peak at the age of 18. In the same three
databases with high NSAID use in young children a
clear seasonality is seen with highest NSAID use in
winter, probably related to prescription of NSAIDs
to young children for fever and fever-like symptoms
(Figure 1). Between countries major differences exist
in the type of NSAID that was used. Ibuprofen was
the most frequently used NSAID (69.3%). Safety and
efficiency of ibuprofen in children are much more
extensively studied than (most) other NSAIDs [10-13].
Two databases from the Netherlands were included
in this study, allowing a comparison between popula-
tions that should have similar characteristics. Since
PHARMO is a pharmacy dispensing database that captures
over-the-counter (OTC) dispensations of NSAIDs, the
prevalence of NSAID exposure was slightly higher for
PHARMO than for IPCI, especially in adolescents. Three
Italian databases participated in the SOS platform and
the prevalence rates for different ages of NSAID use
were very similar for OSSIFF and SISR, but not for
Pedianet (Figure 1). This could be related to the fact that
Pedianet captures all prescriptions, whether reimbursed
or not, plus recommendations on NSAID treatment
made by pediatricians, while OSSIFF and SISR contain
only the reimbursed NSAID dispensing.
Although the SOS platform appears to provide a
unique opportunity to study the safety of NSAIDs in a
large number of children and adolescents, we showed
that the data are still too limited to study the safety of
specific NSAID substances or the safety of NSAIDs in
general for rare adverse drug reactions. Only for ibuprofen
enough exposure time was available in the platform to
investigate the risk of asthma exacerbation (the most
common event) for a ‘weak association’ with a RR of 2.
Data accumulation in platforms like SOS and others is
of utmost importance for the safety evaluation of drugs
in adults and children. The coming decade is likely to
bring enormous expansion of available health care records,
and advancement of data mining and harmonisation
methods. Both the U.S. Food and Drug Administration and
the European Medicines Agency invest in infrastructure
and knowledge expansion in this field. However, our study
shows how difficult it is to study safety in children, when
compared to adults. Because of lower drug consumption –
fortunately – use of these platforms for adequate drug
safety surveillance is more challenging, as are many aspectsof drug research in children. This should emphasize the
responsibility as researchers, clinicians, and policy makers
to facilitate high quality research in this vulnerable
patient group through funding, scholarship, education
and collaboration.
Limitations
Some limitations should be considered. First, in this
analysis, we primarily used alpha = 0.05 as a testing
threshold. To propose a tentative signal for NSAID
safety in the pediatric population, a less stringent testing
threshold may be indicated. For an expected RR of 6, a
‘strong association’, we performed additional power
calculations with a less stringent alpha value of 0.1
(Table 3). This sensitivity analysis did not materially
change our results. Second, our study may not have
captured all NSAID exposure, since many of these
drugs are also available without prescription in all four
countries. We expect any underestimation of NSAID
use in the present study to be minor since most parents
may be reluctant to administer drugs to their children
without having consulted a health care professional. In
addition, people are likely to prefer prescribed over
freely available NSAIDs for financial reasons since
reimbursement is only possible for prescribed drugs.
Third, we observed that rates of NSAID use were low
in the month of August. This is to be expected because
of summer holiday periods during which physician or
pharmacy visits are less likely to occur. Fourth, we only
used diagnosis codes for identification of pediatric
events of interest. We did neither use laboratory values,
medical images nor procedures for event measurement,
therefore potentially missing some events. We expect
the amount of misclassification to be very minor since
most patients with a confirmed diagnosis from these
examinations would have a diagnosis code entered in the
participating databases, as this is important for reim-
bursement. Fifth, we only considered the total person
time of NSAID exposure, thereby possibly overestimating
the possibilities of safety assessment. Issues such as gap
lengths between subsequent NSAID prescriptions and
switching between different substances would have to be
accounted for by design of NSAID safety studies. Biases
related to prevalent NSAID users can be avoided with a
new-user study design [25]. With a new-user design,
however, prevalent NSAID users would be excluded from
the study cohort, thereby resulting in less exposure time
than presented in this analysis.
For the SOS studies, to estimate outcome risks with
NSAID use in children and adolescents, we will consider
case-only designs such as self-controlled case series or
case-crossover [26]. One advantage is that case-only
designs automatically control for all time-invariant
confounders, measured or unmeasured (e.g., gender or
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statistical power to detect a safety signal when compared
with cohort studies or case–control studies, thus offering
a possibility to overcome limited data resources such as
in the present context [27]. For several pediatric outcomes
of interest, the occurrence of the event may change the
probability of subsequent NSAID exposure, either by
contraindication (e.g., acute renal failure and anaphylactic
shock) or increased mortality risk (e.g., acute myocardial
infarction and stroke), thereby violating the event-
independent exposure assumption of the standard
self-controlled case series method [28]. These issues
can be addressed with case-only designs by use of either
an advanced version of the self-controlled case series
method [29-31] or a case-crossover design [32]. The
case-crossover design considers only pre-event time
and can be extended by methods such as the case-
time-control design to account for time trends of drug
exposure [33,34].
Conclusions
NSAID use is common in children and utilization patterns
varied between Germany, Italy, United Kingdom, and
The Netherlands. There is a clear need to study NSAID
safety in children [3]. Although the SOS platform captures
information on a large number of young NSAID users
(1.3 million), even larger data platforms may be needed
to conclusively assess the safety of these drugs in children,
especially for rare events. International collaboration is
needed to adequately study NSAID safety in children.
Advanced versions of case-only study designs may be
indicated to gain statistical power to study NSAID safety
in children.
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